A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor

被引：12

作者：

Montembault, M

Vo-Thanh, G

Deyine, A

Fargeas, V

Villiéras, M

Adjou, A

Dubreuil, D

Esquieu, D

Grégoire, C

Opi, S

Péloponèse, JM

Campbell, G

Watkins, J

de Mareuil, J

Aubertin, AM

Bailly, C

Loret, E

Lebreton, J

机构：

[1] Fac Sci, CNRS, UMR 6513, Organ Synth Lab, F-44322 Nantes 3, France

[2] Fac Tech Sci, Chim Organ Struct Lab, Abidjan, Cote Ivoire

[3] Univ Med, CNRS, FRE, Fac Pharm, F-13385 Marseille 5, France

[4] Inst Virol, INSERM, U 74, F-67000 Strasbourg, France

[5] INSERM, U 524, F-59045 Lille, France

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 06期

关键词：

HIV; inhibitor; Tat protein;

D O I：

10.1016/j.bmcl.2003.12.095

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The HIV-1 Tat protein is a promising target for AIDS therapy, due to its extra-cellular roles against the immune system. From the 2D-NMR structure of Tat, we have designed molecules, called TDS, able to bind to Tat and inhibit HIV-1 replication in vitro. This new family of antivirals is composed of a triphenylene aromatic ring substituted with at least one carbon chain bearing a succinimide group. These ligands are prepared from triphenylene or 2,6, 10-trimethylphenylene in 3-6 steps depending on the target molecule. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：1543 / 1546

页数：4

共 50 条

[1] Discovery of a Tat HIV-1 inhibitor through computer-aided drug design
Esquieu, D
Péloponèse, JM
Opi, S
Gregoire, C
de Mareuil, J
Watkins, J
Campbell, G
Dunot, JP
Sturgis, J
Witvrouw, M
Pannecouque, C
de Clercq, E
Montembault, M
Giang, VT
Villiéras, M
Fargeas, V
Lebreton, J
Loret, EP
SPECTROSCOPY-AN INTERNATIONAL JOURNAL, 2003, 17 (04): : 639 - 645
[2] STRUCTURE OF A NONPEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE - DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN
RUTENBER, E
FAUMAN, EB
KEENAN, RJ
FONG, S
FURTH, PS
DEMONTELLANO, PRO
MENG, E
KUNTZ, ID
DECAMP, DL
SALTO, R
ROSE, JR
CRAIK, CS
STROUD, RM
JOURNAL OF BIOLOGICAL CHEMISTRY, 1993, 268 (21) : 15343 - 15346
[3] Structure-based HIV-1 integrase inhibitor design: a future perspective
Neamati, N
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (02) : 281 - 296
[4] Importance of structure-based studies for the design of a novel HIV-1 inhibitor peptide
Gomara, Maria J.
Perez, Yolanda
Gomez-Gutierrez, Patricia
Herrera, Carolina
Ziprin, Paul
Martinez, Javier P.
Meyerhans, Andreas
Perez, Juan J.
Haro, Isabel
SCIENTIFIC REPORTS, 2020, 10 (01)
[5] Importance of structure-based studies for the design of a novel HIV-1 inhibitor peptide
María J. Gomara
Yolanda Perez
Patricia Gomez-Gutierrez
Carolina Herrera
Paul Ziprin
Javier P. Martinez
Andreas Meyerhans
Juan J. Perez
Isabel Haro
Scientific Reports, 10
[6] Structure-based design of ligands for protein basic domains: Application to the HIV-1 Tat protein
Filikov, AV
James, TL
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1998, 12 (03) : 229 - 240
[7] Structure-based design of ligands for protein basic domains: Application to the HIV-1 Tat protein
Anton V. Filikov
Thomas L. James
Journal of Computer-Aided Molecular Design, 1998, 12 : 229 - 240
[8] Structure-Based Discovery and Characterization of a Preclinical Drug Candidate for the Treatment of HIV-1 Infection
Kang, Dongwei
Yang, Jinxuan
Kong, Lingjin
Luo, Ronghua
Huang, Xusheng
Zhang, Tao
Ma, Mengdi
Feng, Da
Wang, Zhao
Fang, Hao
Zhan, Peng
Zheng, Yongtang
Liu, Xinyong
VIRUSES-BASEL, 2022, 14 (11):
[9] Considerations for Structure-Based Drug Design Targeting HIV-1 Reverse Transcriptase
Arnold, Eddy
Martinez, Sergio E.
Bauman, Joseph D.
Das, Kalyan
MULTIFACETED ROLES OF CRYSTALLOGRAPHY IN MODERN DRUG DISCOVERY, 2015, : 69 - 81
[10] HIV-1 Reverse Transcriptase Structure-Based Drug Design: Crystals to Clinic
Phillips, Chris
Irving, Steve
Ringrose, Heather
Corbau, Romu
Mowbray, Charles
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2007, 63 : S18 - S18

← 1 2 3 4 5 →